Search results for: Innovation Policy Prize
Filter search results
The Economics of the Market for Medicines: 2013 Review
26 March 2013
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2013 activities, he recently gave a comprehensive lecture on…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
Advances in science and technology are producing more and better means for diagnosing disease, matching patients to the best therapies, and tracking the progress of treatment. The potential impact of…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
In this video, Adrian Towse discusses the challenges and importance of appropriately valuing genomic medicine. He addresses both gene therapies and “pharmacogenomics” — those medicines that will allow targeted, precision…
Critical Factors Affecting Pharmaceutical R&D and the Availability of New Drugs
18 June 2013
Dr Jorge Mestre-Ferrandiz, OHE’s Director of Consulting, was a recent guest lecturer at Imperial College London. His comprehensive presentation covered the gamut of issues that influence the rate and direction…
Seminar Updates Project on Time Lags in Medical Research
8 October 2013
Progress on this important UK Medical Research Council project was discussed. A major challenge in biomedical and health research is ensuring that research findings are effectively and efficiently translated from…
Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
Four types of economic incentives for drugs and diagnostics are essential to encouraging more rapid progress in personalised medicine. Adrian Towse, OHE’s Director, and Lou Garrison, a professor at the…
Personalised Medicine and the Value of Molecular Diagnostics: Case Studies
18 December 2013
Progress in personalised medicine is slower than some had expected, partly because of the science and partly because of insufficient economic incentives, particularly for investing in molecular diagnostics. In this…
European Union Pharmaceutical Markets: A Case for Differential Pricing?
11 August 2015
This article looks at how theory could be put into practice suggesting ways to implement a differential pricing system for branded medicines in the EU that can enhance overall welfare….
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those…